Acute hypokalemia may not be an effective way to sensitize the in situ canine heart for sparfloxacin-induced long QT syndrome

Journal of Pharmacological Sciences

Volumn 100, Issue 1, 2006, Pages 88-92

  Chiba, Katsuyoshi ^a   Sugiyama, Atsushi ^b   Watanabe, Kazuo ^a   Takasuna, Kiyoshi ^a   Hashimoto, Keitaro ^b  

^a DAIICHI SANKYO CO   (Japan)

^b UNIVERSITY OF YAMANASHI   (Japan)

Author keywords

Fluoroquinolone; Hypokalemia; Long QT syndrome

Indexed keywords

FUROSEMIDE; HALOTHANE; POTASSIUM; SPARFLOXACIN;

ANESTHESIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DOG; EXPERIMENTAL DESIGN; FEMALE; HEART; HYPOKALEMIA; LONG QT SYNDROME; NONHUMAN; POTASSIUM BLOOD LEVEL; PREDICTION; QT PROLONGATION; RISK ASSESSMENT; SENSITIZATION;

EID: 31544466804     PISSN: 13478613     EISSN: 13478648     Source Type: Journal    
DOI: 10.1254/jphs.SCJ05008X     Document Type: Article

References (15)

1. Tamargo J. Drug-induced torsade de pointes: From molecular biology to bedside. Jpn J Pharmacol. 2000;83:1-19.
2. Anderson ME, Mazur A, Yang T, Roden DM. Potassium current antagonist properties and proarrhythmic consequences of quinolone antibiotics. J Pharmacol Exp Ther. 2001;296:806-810.
3. Chiba K, Sugiyama A, Hagiwara T, Takahashi S, Takasuna K, Hashimoto K. In vivo experimental approach for the risk assessment of fluoroquinolone antibacterial agents-induced long QT syndrome. Eur J Pharmacol. 2004;486:189-200.
4. Chiba K, Sugiyama A, Satoh Y, Shiina H, Hashimoto K. Proarrhythmic effects of fluoroquinolone antibacterial agents: In vivo effects as physiologic substrate for torsades. Toxicol Appl Pharmacol. 2000;169:8-16.
5. Yap YG, Camm AJ. QT prolongation with quinolone antimicrobial agents. In: Hooper DC, Rubinstein E, editors. Quinolone antimicrobial agents. 3rd ed. Washington DC: ASM Press; 2003. p. 421-440.
6. The ICH Steering Committee. The non-clinical evaluation of the potential for delayed ventricular repolarization (QT interval prolongation) by human pharmaceuticals. The International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH). The Guideline was released for consultation under Step 4 of the ICH process in May 2005. http://www.ich.org/
7. Roden DM. Taking the "idio" out of "idiosyncratic": predicting torsades de pointes. Pacing Clin Electrophysiol. 1998;21:1029-1034.
8. Vos MA, van Opstal JM, Leunissen JD, Verduyn SC. Electrophysiologic parameters and predisposing factors in the generation of drug-induced Torsade de Pointes arrhythmias. Pharmacol Ther. 2001;92:109-122.
9. Kirchhof PF, Fabritz CL, Franz MR. Postrepolarization refractoriness versus conduction slowing caused by class I antiarrhythmic drugs: Antiarrhythmic and proarrhythmic effects. Circulation. 1998;97:2567-2574.
10. Kr channel blocker sematilide on the relationship between ventricular repolarization, refractoriness and onset of torsades de pointes. Jpn J Pharmacol. 2002;88:414-421.
11. Van de Water A, Verheyen J, Xhonneux R, Reneman RS. An improved method to correct the QT interval of the electrocardiogram for change in heart rate. J Pharmacol Methods. 1989;22:207-217.
12. Davy JM, Weissenburger J, Ertzbischoff O, Lainee P, Chezalviel F, Poirier JM, et al. Sotalol-induced torsades de pointe in the conscious dog with atrioventricular block: Role of hypokalemia. Arch Mal Coeur. 1988;81:1117-1124.
13. Duker GD, Linhardt GS. An animal model for studying class III-induced proarrhythmias in the halothane-anesthetized dog. J Am Coll Cardiol. 1994;23:326A.
14. Kr. Implications for torsade de pointes and reverse use-dependence. Circulation. 1996;93:407-411.
15. Alarcon OM, Reinosa J, Medina de Caraballo MI, Silva T. Halothane anesthesia and serum electrolytes. J Trace Elem Med Biol. 1996;10:46-49.